Camelia Quek
Overview
Explore the profile of Camelia Quek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Shklovskaya E, Satgunaseelan L, Mao Y, Pires da Silva I, Perry K, et al.
Nat Med
. 2025 Feb;
PMID: 40016450
Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many...
2.
Quek C
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859295
The field of translational bioinformatics is rapidly evolving, driving the convergence of molecular sciences and computational methods with their applications in industrial and clinical practice [...].
3.
Phung N, Pham H, Tran T, Dinh V, Tran N, Tran N, et al.
Diagnostics (Basel)
. 2025 Jan;
15(1.
PMID: 39795618
: Primary amebic meningoencephalitis (PAM) caused by is a rare and devastating infection of the central nervous system, often diagnosed late, due to its rapid progression and nonspecific symptoms. We...
4.
Elewaut A, Estivill G, Bayerl F, Castillon L, Novatchkova M, Pottendorfer E, et al.
Nature
. 2024 Nov;
637(8046):716-725.
PMID: 39604727
The tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses. Within the tumour microenvironment, CD8 T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions...
5.
Quek C, Pratapa A, Bai X, Al-Eryani G, Pires da Silva I, Mayer A, et al.
Cell Rep
. 2024 Jun;
43(7):114392.
PMID: 38944836
Heterogeneous resistance to immunotherapy remains a major challenge in cancer treatment, often leading to disease progression and death. Using CITE-seq and matched 40-plex PhenoCycler tissue imaging, we performed longitudinal multimodal...
6.
Tian J, Bai X, Quek C
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38674070
Cancer comprises malignant cells surrounded by the tumor microenvironment (TME), a dynamic ecosystem composed of heterogeneous cell populations that exert unique influences on tumor development. The immune community within the...
7.
Tian J, Quek C
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673829
Melanoma is the leading cause of global skin cancer-related death and currently ranks as the third most commonly diagnosed cancer in Australia. Melanoma patients with in-transit metastases (ITM), a type...
8.
Bai X, Attrill G, Gide T, Ferguson P, Nahar K, Shang P, et al.
Nat Commun
. 2024 Apr;
15(1):3014.
PMID: 38589406
The biological underpinnings of therapeutic resistance to immune checkpoint inhibitors (ICI) in adolescent and young adult (AYA) melanoma patients are incompletely understood. Here, we characterize the immunogenomic profile and spatial...
9.
Adegoke N, Gide T, Mao Y, Quek C, Patrick E, Carlino M, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37865395
Background: Tumor microenvironment (TME) characteristics are potential biomarkers of response to immune checkpoint inhibitors in metastatic melanoma. This study developed a method to perform unsupervised classification of TME of metastatic...
10.
Manolios N, Pham S, Hou G, Du J, Quek C, Hibbs D
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298286
T-cell recognition of antigens is complex, leading to biochemical and cellular events that impart both specific and targeted immune responses. The end result is an array of cytokines that facilitate...